Get the Stockscreener App
5.90
1.67%
-0.10
Serina Therapeutics Inc stock is traded at $5.90, with a volume of 25,689.
It is down -1.67% in the last 24 hours and up +1.95% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$6.00
Open:
$5.9899
24h Volume:
25,689
Relative Volume:
2.27
Market Cap:
$58.82M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.85%
1M Performance:
+1.95%
6M Performance:
+24.21%
1Y Performance:
+0.00%
1-Day Range:
$5.85
$6.09
1-Week Range:
$5.70
$6.09
52-Week Range:
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
5.90 | 58.81M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail
Serina Therapeutics Appoints Dr. Stephen Brannan to Board of Directors to Enhance CNS Therapeutic Development - Nasdaq
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors - GlobeNewswire
Karuna's $14B Exit Architect Joins Serina Board: CNS Drug Development Expert to Guide Neural Pipeline - Stock Titan
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire
Parkinson's Drug Developer Serina Therapeutics Expands Team with Equity Incentives Worth 15,000 Shares - Stock Titan
Serina Therapeutics Advances SER-252 for Parkinson’s Disease and Strengthens Leadership and Financial Position - Nasdaq
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times
Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan
Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire
Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan
Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada
Serina Therapeutics Secures $5 Million Funding - MarketScreener
Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com
Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire
Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan
Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
Serina Therapeutics Secures $5 Million for SER-252 Trials - TipRanks
Serina Therapeutics Receives Second $5 Million Tranche to - GlobeNewswire
Parkinson's Breakthrough: Serina Therapeutics Lands Premium-Priced $5M Investment to Advance Novel Treatment - StockTitan
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Serina Therapeutics Shares Rise After Sale of UniverXome Subsidiary - MarketWatch
Serina Therapeutics Sells UniverXome Subsidiary - MarketWatch
Serina Therapeutics Announces Sale of UniverXome Subsidiary - GlobeNewswire
Serina Therapeutics Achieves Debt-Free Status After $11.2M UniverXome Sale, Sharpens Focus on Parkinson's Drug - StockTitan
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors - GlobeNewswire
Serina Therapeutics, Inc. Appoints Karen J. Wilson to its Board of Directors -January 14, 2025 at 05:25 pm EST - Marketscreener.com
Serina Therapeutics Inc Stock (SER) Financials Data
There is no financial data for Serina Therapeutics Inc (SER). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
6.48%
Cap:
|
Volume (24h):